Pharma BD Deal Intelligence
Sanofi acquired Ablynx for $4.8B, a Belgian biotechnology firm.
Sanofi to acquire Ablynx for $4.8 billion, gaining a pipeline of more than 45 proprietary and partnered nanobody candidates across hematology, inflammation,…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Sanofi acquired Ablynx for $4.8B, a Belgian biotechnology firm.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Ablynx NV (this deal) | 2018 | $4.8B | 67 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2018 deals · Sanofi SA deals · Immunology deals